<DOC>
	<DOC>NCT01555346</DOC>
	<brief_summary>Whole blood samples will be collected from high-risk pregnant women to validate the clinical performance of the SEQureDx Trisomy 21 Test.</brief_summary>
	<brief_title>Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies</brief_title>
	<detailed_description />
	<mesh_term>Down Syndrome</mesh_term>
	<mesh_term>Aneuploidy</mesh_term>
	<criteria>Pregnant woman 18 years of age or older at 10 22 weeks gestation inclusive Subject has one or more high risk indicator for fetal chromosome 21 aneuploidy Subject provides signed and dated informed consent Subject agrees to provide a whole blood sample Fetal demise at the time of the blood draw Previous specimen donation under this protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Down syndrome</keyword>
	<keyword>fetal aneuploidy</keyword>
	<keyword>trisomy</keyword>
	<keyword>noninvasive prenatal test</keyword>
</DOC>